Notes to the Condensed Consolidated Interim Financial Statements of the Bayer Group as of September 30, 2016

Key Data by Segment

Key Data by Segment – Third Quarter 2016

 

 

Pharmaceuticals

 

Consumer Health

 

Crop Science

 

Animal Health

 

 

Q3
2015

Q3
2016

 

Q3
2015

Q3
2016

 

Q3
2015

Q3
2016

 

Q3
2015

Q3
2016

 

 


million


million

 


million


million

 


million


million

 


million


million

2015 figures restated

1

For definition see Interim Group Management Report, “Overview of Sales, Earnings and Financial Position.”

2

For definition see Interim Group Management Report, “Calculation of EBIT(DA) Before Special Items.”

3

For definition see Interim Group Management Report, “Statements of Cash Flows.”

Net sales (external)

 

3,870

4,152

 

1,424

1,425

 

2,081

2,057

 

357

360

Change1

 

+13.7%

+7.3%

 

+41.4%

+0.1%

 

+9.6%

–1.2%

 

+8.2%

+0.8%

Currency-adjusted change1

 

+10.5%

+7.6%

 

+40.1%

+3.6%

 

+2.2%

 

+1.8%

+2.5%

Intersegment sales

 

8

7

 

 

7

7

 

8

6

Net sales (total)

 

3,878

4,159

 

1,424

1,425

 

2,088

2,064

 

365

366

EBIT2

 

940

1,097

 

209

194

 

187

135

 

70

81

EBIT before special items2

 

947

1,103

 

241

223

 

191

206

 

77

82

EBITDA before special items2

 

1,253

1,421

 

340

328

 

316

318

 

84

89

Gross cash flow3

 

857

998

 

207

236

 

213

187

 

53

60

Net cash flow3

 

943

998

 

230

215

 

603

1,027

 

100

80

Depreciation, amortization and impairments

 

306

319

 

99

107

 

126

112

 

9

7

Continuation of the previous table

 

 

Reconciliation

 

 

 

 

 

 

 

 

 

All Other Segments

 

Corporate Functions and Consolidation

 

Life Sciences

 

Covestro

 

Group

 

 

Q3 2015

Q3 2016

 

Q3 2015

Q3 2016

 

Q3 2015

Q3 2016

 

Q3 2015

Q3 2016

 

Q3 2015

Q3 2016

 

 


million


million

 


million


million

 


million


million

 


million


million

 


million


million

2015 figures restated

1

For definition see Interim Group Management Report “Overview of Sales, Earnings and Financial Position.”

2

For definition see Interim Group Management Report “Calculation of EBIT(DA) Before Special Items.”

3

For definition see Interim Group Management Report “Statements of Cash Flows.”

Net sales (external)

 

262

261

 

1

3

 

7,995

8,258

 

3,009

3,004

 

11,004

11,262

Change1

 

+0.4%

–0.4%

 

 

+15.9%

+3.3%

 

–0.9%

–0.2%

 

+10.7%

+2.3%

Currency-adjusted change1

 

+1.1%

+0.4%

 

 

+11.8%

+4.5%

 

–7.7%

+1.0%

 

+5.8%

+3.5%

Intersegment sales

 

575

410

 

(616)

(447)

 

 

18

17

 

Net sales (total)

 

837

671

 

(615)

(444)

 

 

3,027

3,021

 

11,004

11,262

EBIT2

 

2

13

 

(53)

(123)

 

1,355

1,397

 

217

398

 

1,572

1,795

EBIT before special items2

 

58

27

 

(42)

(119)

 

1,472

1,522

 

304

398

 

1,776

1,920

EBITDA before special items2

 

105

80

 

(40)

(118)

 

2,058

2,118

 

472

564

 

2,530

2,682

Gross cash flow3

 

(166)

105

 

(40)

(82)

 

1,124

1,504

 

310

447

 

1,434

1,951

Net cash flow3

 

(114)

106

 

144

(57)

 

1,906

2,369

 

326

668

 

2,232

3,037

Depreciation, amortization and impairments

 

47

53

 

2

1

 

589

599

 

171

166

 

760

765

Key Data by Segment – 9 Month 2016

 

 

Pharmaceuticals

 

Consumer Health

 

Crop Science

 

Animal Health

 

 

9M 2015

9M 2016

 

9M 2015

9M 2016

 

9M 2015

9M 2016

 

9M 2015

9M 2016

 

 


million


million

 


million


million

 


million


million

 


million


million

2015 figures restated

1

For definition see Interim Group Management Report, “Overview of Sales, Earnings and Financial Position.”

2

For definition see Interim Group Management Report, “Calculation of EBIT(DA) Before Special Items.”

3

For definition see Interim Group Management Report, “Statements of Cash Flows.”

4

Full-time equivalents

Net sales (external)

 

11,322

12,145

 

4,570

4,498

 

7,723

7,511

 

1,171

1,194

Change1

 

+15.0%

+7.3%

 

+59.7%

–1.6%

 

+8.6%

–2.7%

 

+15.0%

+2.0%

Currency-adjusted change1

 

+8.7%

+9.3%

 

+55.1%

+3.3%

 

+1.2%

+0.7%

 

+4.8%

+5.2%

Intersegment sales

 

26

22

 

2

4

 

25

24

 

15

8

Net sales (total)

 

11,348

12,167

 

4,572

4,502

 

7,748

7,535

 

1,186

1,202

EBIT2

 

2,459

2,783

 

574

627

 

1,603

1,602

 

240

288

EBIT before special items2

 

2,568

3,031

 

756

720

 

1,682

1,706

 

285

290

EBITDA before special items2

 

3,531

4,034

 

1,071

1,039

 

2,059

2,070

 

306

311

Gross cash flow3

 

2,418

2,830

 

675

758

 

1,433

1,421

 

208

215

Net cash flow3

 

2,246

2,042

 

676

653

 

574

1,449

 

305

108

Depreciation, amortization and impairments

 

967

1,236

 

315

335

 

383

364

 

44

21

Number of employees (as of Sep. 30)4

 

41,124

39,994

 

13,756

12,909

 

23,446

22,323

 

3,820

3,982

Continuation of the previous table

 

 

Reconciliation

 

 

 

 

 

 

 

 

 

All Other Segments

 

Corporate Functions and Consolidation

 

Life Sciences

 

Covestro

 

Group

 

 

9M 2015

9M 2016

 

9M 2015

9M 2016

 

9M 2015

9M 2016

 

9M 2015

9M 2016

 

9M 2015

9M 2016

 

 


million


million

 


million


million

 


million


million

 


million


million

 


million


million

2015 figures restated

1

For definition see Interim Group Management Report, “Overview of Sales, Earnings and Financial Position.”

2

For definition see Interim Group Management Report, “Calculation of EBIT(DA) Before Special Items.”

3

For definition see Interim Group Management Report, “Statements of Cash Flows.”

4

Full-time equivalents

Net sales (external)

 

803

767

 

3

5

 

25,592

26,120

 

9,208

8,829

 

34,800

34,949

Change1

 

–1.5%

–4.5%

 

 

+18.2%

+2.1%

 

+5.8%

–4.1%

 

+14.6%

+0.4%

Currency-adjusted change1

 

–1.2%

–3.8%

 

 

+11.8%

+5.0%

 

–3.2%

–2.6%

 

+7.5%

+3.0%

Intersegment sales

 

1,705

1,570

 

(1,818)

(1,684)

 

 

45

56

 

Net sales (total)

 

2,508

2,337

 

(1,815)

(1,679)

 

 

9,253

8,885

 

34,800

34,949

EBIT2

 

45

34

 

(315)

(182)

 

4,606

5,152

 

714

1,101

 

5,320

6,253

EBIT before special items2

 

123

73

 

(293)

(167)

 

5,121

5,653

 

902

1,101

 

6,023

6,754

EBITDA before special items2

 

259

221

 

(288)

(163)

 

6,938

7,512

 

1,402

1,611

 

8,340

9,123

Gross cash flow3

 

102

505

 

(221)

(130)

 

4,615

5,599

 

981

1,282

 

5,596

6,881

Net cash flow3

 

(57)

273

 

318

(90)

 

4,062

4,435

 

849

1,146

 

4,911

5,581

Depreciation, amortization and impairments

 

136

148

 

5

4

 

1,850

2,108

 

525

510

 

2,375

2,618

Number of employees (as of Sep. 30)4

 

19,086

19,550

 

709

759

 

101,941

99,517

 

15,698

15,659

 

117,639

115,176